Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing 3 Mg And 12 Mg Of Ly3202626 With Placebo Over 52 Weeks In Approxima
Posted Date: May 15, 2019
- Investigator: Lawrence Goldstick
- Type of Study: Drug
This study is being done to see how safe a new investigational drug is and how well it might work to help people with Alzheimer?s disease. ?Investigational? means that the drug being tested has not been approved for sale or routine clinical use in the United States by the U.S. Food and Drug Admin
Criteria:
You Cannot Be In This Study If: ? You Have Certain Neurologic Diseases Or Psychiatric Disorders. ?
Keywords:
Dementia, Eli Lilly, Alzheimer?S Disease, Ly3202626
For More Information:
Samantha Maldonado
(937) 535-5012
samantha.maldonado@uchealth.com